Thrivent Financial for Lutherans
MRSN

Thrivent Financial for Lutherans’s Mersana Therapeutics MRSN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,323
Closed -$191K – 2476
2023
Q2 		$191K Sell
2,323
-114
-5% -$16.7K ﹤0.01% 2411
2023
Q1 		$250K Hold
2,437
– – ﹤0.01% 2336
2022
Q4 		$357K Buy
+2,437
New +$412K ﹤0.01% 2216
2021
Q1 		– Sell
-1,301
Closed -$865K – 2552
2020
Q4 		$865K Buy
1,301
+370
+40% +$206K ﹤0.01% 1847
2020
Q3 		$433K Sell
931
-381
-29% -$193K ﹤0.01% 2039
2020
Q2 		$768K Buy
1,312
+370
+39% +$126K ﹤0.01% 1675
2020
Q1 		$137K Buy
+942
New +$165K ﹤0.01% 2182

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Thrivent Financial for Lutherans's MRSN Position: Q3 2023 in Review

Thrivent Financial for Lutherans sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 2,323 shares — an estimated $191K sold.

Thrivent Financial for Lutherans first reported a position in MRSN in Q1 2020 and held it in 7 quarters. The position peaked at $865K in Q4 2020. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Thrivent Financial for Lutherans reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 2,323 Mersana Therapeutics shares in Q3 2023, an estimated $191K.
  • Thrivent Financial for Lutherans first reported a position in Mersana Therapeutics in Q1 2020 and held it in 7 quarters.
  • Thrivent Financial for Lutherans's Mersana Therapeutics position peaked at $865K in Q4 2020.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2023, filed 14 Nov 2023.